BIOCRYST PHARM
BIOCRYST PHARM operates in Diversified Metals & Mining.
Market Cap & Net Worth: BIOCRYST PHARM (BO1)
BIOCRYST PHARM (MU:BO1) has a market capitalization of $71.93K (€70.08K) as of March 18, 2026. Listed on the MU stock exchange, this Germany-based company holds position #41727 globally and #6371 in its home market, demonstrating a -1.45% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BIOCRYST PHARM's stock price €7.35 by its total outstanding shares 9532 (9.53K).
BIOCRYST PHARM Market Cap History: 2015 to 2026
BIOCRYST PHARM's market capitalization history from 2015 to 2026. Data shows change from $95.89K to $71.93K (-0.44% CAGR).
BIOCRYST PHARM Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BIOCRYST PHARM's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
BIOCRYST PHARM's market cap is 0.00 times its annual revenue
0.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $59.87K | $26.35 Million | -$55.14 Million | 0.00x | N/A |
| 2017 | $41.16K | $25.19 Million | -$65.78 Million | 0.00x | N/A |
| 2018 | $67.32K | $20.65 Million | -$101.25 Million | 0.00x | N/A |
| 2019 | $26.81K | $48.84 Million | -$108.90 Million | 0.00x | N/A |
| 2020 | $54.60K | $17.81 Million | -$182.81 Million | 0.00x | N/A |
| 2021 | $115.06K | $157.17 Million | -$184.06 Million | 0.00x | N/A |
| 2022 | $101.29K | $270.83 Million | -$247.12 Million | 0.00x | N/A |
| 2023 | $53.46K | $331.41 Million | -$226.54 Million | 0.00x | N/A |
Competitor Companies of BO1 by Market Capitalization
Companies near BIOCRYST PHARM in the global market cap rankings as of March 18, 2026.
Key companies related to BIOCRYST PHARM by market ranking:
- BERKSHIRE HATH-A (BE:BRH): Ranked #2328 globally with a market cap of $6.43 Billion USD ( €6.27 Billion EUR).
- BERKSHIRE HATH-A - Dusseldorf Stock Exchang (DU:BRH): Ranked #2395 globally with a market cap of $6.17 Billion USD ( €6.02 Billion EUR).
- Itissalat Al-Maghrib (IAM) S.A (PINK:MAOTF): Ranked #3760 globally with a market cap of $3.25 Billion USD.
- NET ONE SYSTEMS (MU:NOX): Ranked #4660 globally with a market cap of $2.24 Billion USD ( €2.18 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #2328 | BERKSHIRE HATH-A | BE:BRH | $6.43 Billion | €634500.00 |
| #2395 | BERKSHIRE HATH-A - Dusseldorf Stock Exchang | DU:BRH | $6.17 Billion | €638000.00 |
| #3760 | Itissalat Al-Maghrib (IAM) S.A | PINK:MAOTF | $3.25 Billion | $14.80 |
| #4660 | NET ONE SYSTEMS | MU:NOX | $2.24 Billion | €1000000.00 |
BIOCRYST PHARM Historical Marketcap From 2015 to 2026
Between 2015 and today, BIOCRYST PHARM's market cap moved from $95.89K to $ 71.93K, with a yearly change of -0.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €71.93K | +12.28% |
| 2025 | €64.07K | -9.61% |
| 2024 | €70.88K | +32.58% |
| 2023 | €53.46K | -47.22% |
| 2022 | €101.29K | -11.97% |
| 2021 | €115.06K | +110.75% |
| 2020 | €54.60K | +103.65% |
| 2019 | €26.81K | -60.17% |
| 2018 | €67.32K | +63.54% |
| 2017 | €41.16K | -31.25% |
| 2016 | €59.87K | -37.56% |
| 2015 | €95.89K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of BIOCRYST PHARM was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $71.93K USD |
| MoneyControl | $71.93K USD |
| MarketWatch | $71.93K USD |
| marketcap.company | $71.93K USD |
| Reuters | $71.93K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.